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Objectives: Recent consensus guidelines do not advocate universal thyroid func-
tion screening during pregnancy but recommend testing high-risk pregnant women 
with a personal history of thyroid or other autoimmune disorders or with a family 
history of thyroid disorders. Maternal subclinical hypothyroidism during pregnancy 
is associated with various adverse outcomes. The present study aims to assess 
efficiency of the targeted high-risk case-finding approach in identifying women 
with thyroid dysfunction during early pregnancy. MethOds: A comprehensive lit-
erature search was done in PubMed and EMBASE databases till July 2012 for studies 
related to screening of thyroid dysfunction. Data was extracted from each relevant 
article. The primary estimate was pooled odds ratio with 95% CI. Data analysis was 
done by Comprehensive Meta Analysis software. Heterogeneity was assessed by 
I2 statistics. Publication bias was assessed using Begg and Egger test. Sensitivity 
analysis was also performed. Results: A total of 5 studies (published between 
2007 and 2011) were found to be pertinent after exclusion of irrelevant studies. 
Because of significant heterogeneity, a random effects model was chosen. For the 
effectiveness of universal screening, pooled odds ratio was found to be 2.87 (95% 
CI, 1.60-4.94, p= 0.00). cOnclusiOns: Targeted thyroid function testing of only the 
high-risk group would miss about one third of pregnant women with overt/ sub-
clinical hypothyroidism.
PRM13
DesaRRollo De Una escala De estRUctURas Y PRoceso PaRa la 
evalUación De los centRos De HeMoDiálisis
Scarpitta C., Saona G., Leiva G., Gambogi R., Opertti A.
Fondo Nacional de Recursos, Montevideo, Uruguay
ObjectivOs: Desarrollar una escala de indicadores de calidad de estructuras 
y procesos para los centros de hemodiálisis del Uruguay. MetOdOlOgíAs: Un 
conjunto de expertos nacionales elaboró una lista de indicadores basados en 
estándares que fueron evaluados mediante visitas técnicas en los centros desde 
2004 hasta la actualidad. Mediante el Análisis de Coordenadas Principales (ACoP) 
y la distancia de Gower se estudió el conjunto de indicadores buscando obtener 
un número reducido de factores que expliquen una proporción importante de la 
varianza del sistema de indicadores en el período 2007 a 2010. Se construyó la 
escala de estructuras y procesos empleando como ponderación la mediana de 
la distancia euclidea entre los indicadores para el espacio de factores obtenidos 
en el ACoP. Mediante estadística descriptiva se analizó el comportamiento de la 
escala en el tiempo y respecto de los indicadores originales. Aplicando el criterio 
de Kaiser se seleccionaron los dos primeros factores del ACoP (varianza expli-
cada 37,63%), el análisis presentó un índice de estrés de 0,1646. ResultAdOs: La 
escala desarrollada mostró una tendencia temporal de mejora en la calidad de 
las estructuras y procesos brindados por los centros de hemodiálisis. También se 
observó una asociación significativa con varias de las dimensiones de estructuras 
y procesos evaluados. cOnclusiOnes: Se considera que el instrumento desar-
rollado es adecuado para la valoración global de las prestaciones en hemodiálisis 
en las áreas de estructura y procesos.
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aPPlieD coMPaRison of Meta-analYsis tecHniqUes
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Meta-analysis is an approach that combines findings from similar studies. The 
aggregation of study-level data can provide precise estimates for outcomes of inter-
est, allow for unique treatment comparisons, and explain differences arising from 
conflicting study results. Proper meta-analysis includes five basic steps: identify 
relevant studies; extract summary data; compute study effect sizes, perform statisti-
cal analysis; and interpret and report the results. Objectives: This study aims to 
review meta-analysis methods and their assumptions, apply various meta-tech-
niques to empirical data, and compare the results from each method. MethOds: 
Three different meta-analysis techniques were applied to a dataset examining the 
effects of the bacille Calmette-Guerin (BCG) vaccine on tuberculosis (TB). Fixed-
effect, random-effect modeling and meta-regression were applied for analysis, with 
added study-level covariates. Overall and stratified results, by geographic latitude 
were reported. Results: Estimates of treatment effect differed depending on the 
technique applied. When a fixed effect model was applied to estimate the effect 
of a vaccination against tuberculosis, the log odds ratio was -0.436 (confidence 
interval [CI: -0.528, -0.344]). After testing for heterogeneity and fitting a random 
effects model, the estimate was reduced to -0.741 (CI [-1.12, -0.352]), and the CI 
became wider. When covariates were added to the model to explain the heteroge-
neity, the treatment effect was reduced even further. All three techniques showed 
statistically significant effects from the vaccination. However, once covariates 
were added, efficacy diminished. Independent variables, such as the latitude of 
the location in which the study was performed, appeared to be partially driving the 
results. cOnclusiOns: Meta-analysis is useful to draw general conclusions from 
a variety of studies. However, proper study and model selection are important to 
ensure the correct interpretation of results. Basic meta-analysis models are fixed-
effects, random-effects, and meta-regression.
ReseaRcH on MetHoDs – study Design
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Objectives: To evaluate, through biomechanical tests, which synthetic material 
used for the manufacturing of test especimens (ABS plastic, polyamide, and polyure-
thane) shows a better biomechanical behavior for in vitrosimulations of load resist-
ance of a fixation method established to mandibular SSRO [Sagittal Split Ramus 
Osteotomy]. MethOds: 30 synthetic and standardized replicas of human hemimandi-
bles with SSRO were divided into 3 groups of 10 samples each: Group A - ABS plastic, 
Group B - Polyamide, and Group C - Polyurethane. These were fixed by three positional 
bicortical screws (16 mm length, 2.0 mm system), in an inverted “L” pattern, using 
drilling guides and advancement of 5 mm. Each sample was subjected to a vertical 
linear load and the load resistance values recorded at 1, 3, 5, 7, and 10mm displace-
ment. The standard deviations and means were compared using analysis of variance 
(p< 0.05) and Tukey’s test. Results: It was observed a tendency for lower values in 
group B than in groups A and C. In displacements of 3 and 5 mm, there was a differ-
ence between groups A and C to group B (p< 0.05). In displacements of 7 and 10 mm, 
there was a difference among the 3 groups, the highest values being found in group 
C and the lowest ones in group B (p< 0.05). cOnclusiOnes: Taking into considera-
tion the results achieved and the behavior of each material used as substrate, we can 
consider that ABS plastic was very flexible and polyurethane very rigid. On the other 
hand, polyamide samples behaved more likely to the human cortical bone, which 
can be validated to perform load tests, for SSRO, compared to other tested materials.
PRM10
calibRation of a cost-effectiveness MoDel to evalUate tHe 
incoRPoRation of a qUaDRivalent HPv tYPes 6, 11, 16, 18 vaccine in 
aRgentina: Disease bURDen coMPonent
Pichon-Riviere A., Caporale J., Alcaraz A., Bardach A., Klein K., Rey Ares L., Augustovski F.
Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina
Objectives: To calibrate the disease burden component (mortality and incidence 
rates from cervical cancer) of a cost-effectiveness model that aims to evaluate the 
incorporation of a quadrivalent HPV Type 6, 11, 16, 18 vaccine in Argentina. MethOds: 
We adapted a previously developed mathematical model (Elbasha 2010) to evaluate 
the health and economic impact of routine vaccination of 11 years old females. The 
model is a dynamic transmission model which estimates the direct and indirect (via 
herd immunity) health benefits of vaccination. Individuals enter the model as they 
are born; move between successive age groups at an age, gender and sexual activity 
specific rates, and exit the model as they die. A systematic search on effectiveness, 
local epidemiology, resource use and costs was undertaken to populate the model. 
Selected intermediate parameters (probability of transmitting genital HPV infection 
per sexual partnership by HPV genotype, and percent of females with cervical cancer 
that recognize their symptoms and seek treatment) were used for calibration. The 
perspective used was that of the health care system, with a horizontal span of 100 
years and a rate of discount of 5% for costs and health effects. Results: The model 
was properly calibrated with results in a range of +/- 1% as compared to national 
vital statistics and Globocan. The model showed an incidence of 5,285 new cases of 
HPV 16&18 related cervical cancers per year in Argentina and 1,511 deaths for 2013. 
Eighty-seven and 80% of incident cases and deaths were concentrated in the 35 to 85 
age group, and a median age of death of 55 years. cOnclusiOns: The model proved 
to be an evidence-based, internally valid tool for the assessment of the main HPV 
related disease burden and can serve as the basis for the further evaluation of the 
cost-effectiveness of HPV routine vaccination in Argentina.
ReseaRcH on MetHoDs – Patient-Reported outcomes studies
PRM11
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ObjectivOs: Evaluar la calidad de vida relacionada con la salud en pacientes con pso-
riasis, medida a través del Dermatology Life Quality Index (DLQI). MetOdOlOgíAs: 
Se realizó una revisión sistemática en Pubmed, Cochrane Library, Embase y CINAHL 
sobre la calidad de vida relacionada con la salud en pacientes con psoriasis leve, 
moderada y severa. Se incluyeron artículos que evaluarán la calidad de vida en su con-
dición basal mediante la escala DLQI y se reportó el resultado utilizando el Psoriasis 
Assessment and Severity Index (PASI) como resultado secundario. La búsqueda sólo 
incluyó estudios en inglés publicados desde 1994 hasta agosto de 2012. Se excluyeron 
los artículos que comparaban diferentes tipos de tratamiento en términos de mejoría 
de la calidad de vida antes y después de la administración del medicamento, así 
como la evaluación de la calidad de vida en diferentes variantes de la enfermedad 
tales como la artritis psoriática y psoriasis de las uñas. ResultAdOs: Se identifi-
caron ocho artículos que cumplieron con los criterios de inclusión y exclusión que 
evaluaban la calidad de vida relacionada con la salud en pacientes con psoriasis leve 
y moderada mediante la escala DLQI. Se evidenció una pérdida de la calidad de vida 
en los pacientes con psoriasis, en sus actividades diarias y de trabajo, así como en la 
vida sexual. El promedio de DLQI estuvo entre 6,4 a 10,8; se observó una gran variabi-
lidad en la duración de la enfermedad entre 17,6 y 28,9 años. Un total de dos estudios 
reportaron el PASI, el cual estuvo entre 6,53 y 10,5, lo que indica enfermedad leve y 
moderada. cOnclusiOnes: La psoriasis afecta la calidad de vida de los pacientes 
que padecen la enfermedad tanto en su forma leve como moderada, y este deterioro 
es superior a los encontrados en enfermedades tales como acné, vitíligo, alopecia y 
urticaria, entre otras enfermedades.
ReseaRcH on MetHoDs – statistical Methods
PRM12
tHYRoiD DYsfUnction Detection in PRegnancY: UniveRsal scReening 
oR taRgeteD HigH-Risk case finDing? a Meta-analYsis
Gudala K., Bansal D., Kandikatla L.R., Krishna P.S.R.
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non-pharmacological cost avoidance assessment we determined that apixaban can 
be a cost saving alternative in the long term. Versus SoC (warfarin), apixaban may 
be the only NOAC with consistent benefit on all relevant events. Consistent with 
trial data, lifetime modeling suggested reduction in the mortality.
Pcv2
coMoRbiDities associateD to atRial fibRillation (af) in selecteD 
latin aMeRica coUntRies
Leyva-Bravo V.1, Soriano M.A.1, González-Rojas G.L.1, Galindo-Rodriguez J.A.2, Diaz G.F.3
1IMS Health, Mexico City, Mexico, 2Instituto de Salud Dr. Hernan Alessandri, Santiago, Chile, 
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Objectives: AF is the most common chronic cardiac arrhythmia worldwide and is 
an important risk factor for morbidity related mainly to an increased risk of cerebro-
vascular events and heart failure. This study examined the prevalence of comor-
bidities among patients receiving treatment for AF in 4 Latin America countries to 
convey a more comprehensive picture of the total disease burden. MethOds: For 
study purposes, co-morbidity was defined as the presence of one or more disorders 
in addition to a primary disease, or the effect of such additional disorders. A 3-step 
process was conducted in order to understand treatment patterns for patients suffer-
ing from AF: 1) health care assessment per country; 2) evaluate patient’s information; 
and 3) data analysis to understand and determine treatment algorithms. Data were 
collected through 59 face-to-face interviews with cardiologists in Argentina, Brazil, 
Chile, and Venezuela. Results: Analysis per country suggested that, in Chile and 
Venezuela, 98% and 94% of patients, respectively, reported at least one co-morbidity. 
In Argentina this pattern was observed in 81% of the patients, whereas in Brazil 
this was 78%. Findings revealed that the main 5 comorbidities associated with AF 
were: 1) Hypertension: LatAm 43%, Argentina 28%, Brazil 45%, Chile 43%, Venezuela 
33%; 2) Dyslipidemia: LatAm 22%, Argentina 11%, Brazil 25%, Chile 21%, Venezuela 
18%; 3) Diabetes: LatAm 13%, Argentina 8%, Brazil 11%, Chile 10%, Venezuela 18%; 
4) Cardiopathies: LatAm 8%, Argentina 4%, Brazil 8%, Chile 8%, Venezuela 9%; 
and 5) Thyroid disease: LatAm 7%, Argentina 4%, Brazil 3%, Chile 12%, Venezuela 
9%. cOnclusiOns: Overall, the analysis suggests that hypertension is the main 
co-morbidity associated with AF, followed by dyslipidemia and diabetes. The health 
burden carried by patients often extends far beyond AF. Physicians should carefully 
consider comorbidities and concomitant medications when managing patients.
Pcv3
icebeRg PHenoMenon of HeaRt failURe in HosPitalizeD Patients:  
a MUlticentRic cRoss sectional stUDY
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Objectives: Heart failure (HF) ranks high in hospital utilization, cost and quality/
safety consequences. We studied occult HF as secondary diagnosis (2Dx) in a multi-
centric study of the A-HCUPs. MethOds: A multi-centric cross sectional study of 1 
year hospital discharges adapted HCUPs for Argentina. We estimated HF by HCUPs’ 
CCS#108 SL (heart failure) in 2Dx to measure submerged HF; obtained HF in first diag-
nosis (1Dx), and 365 day readmissions (ReH), < 30 day ReH, mortality and case fatality. 
2Dx1= in first secondary Dx; 2Dx5= fifth 2Dx, etc. International dollars PPP, (UN Data: 
1Arg$ = 1.608 PPP, 2008) were used. Results: Among 45466 discharges ≥ 19 years 
old, we found 1178 discharges with CCS#108 among 1Dx (incidence: 2,59%*; 95%CI 
2,44-2,74%); mortality 0,24% ** (95%CI 0,20-0,29%); 365 days ReH was 60,9% (95%CI 58,1- 
63,7%) and < 30 day ReH of 18,1% (95%CI 15,9- 20,3%). 864 discharges had CCS #108 (HF) 
among any 2Dx (from 1 to 10 2Dx), (incidence: 1,90%; 95%CI 1,77-2,03%) (p< 0,001 vs*), 
descending from 2Dx1: 316, 2Dx5: 89; and 2Dx8: 36 discharges. HF was one among 
several multi-morbid conditions. Outcomes of discharges with 2Dx1 are 365 day ReH: 
57,3 % (95%CI 51,8-62,7%) and < 30 day ReH: 17,1% (95%CI 12,9- 21,2%), mortality 0,09 
(95%CI 0,06-0,12%,(p< 0,001 vs**), case fatality: 12,66% (95%CI 8,99- 16,32%). Mean cost 
per discharge was 7 907 I$ PPP and median cost 1 917 I$PPP for HF in 1Dx; while mean 
was 23316 I$PPP and median cost 12796 I$PPP for CCS #108 in 2Dx5. cOnclusiOns: 
HF is the leading CCS among several criteria of ranking of discharges. Is one of the 
leading causes of admissions as detected by 1Dx. However, HF is frequently sub-
merged as a 2Dx, causes significant mortality, costs and readmissions (ReH). Quality, 
safety and economic studies should consider HF as secondary diagnosis.
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PeRManent tRansvenoUs leaD extRaction: factoRs inflUencing tHe 
DifficUltY of tHe PRoceDURe
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Objectives: Transvenous lead extraction is increasingly required. The aim of this 
study was to determine which factors influence the difficulty of a lead extraction 
procedure through the analysis of a high-volume centre database. MethOds: A 
total of 889 permanent leads were extracted from 469 patients. Factors influencing 
the difficulty of a procedure were assessed using a multivariate logistic regres-
sion model. The fluoroscopy time of the procedure was taken as index of diffi-
culty. Results: From January 2003 to December 2012 , 932 of 946 (98.5%) leads were 
completely removed. Major complications occurred in 1.3% patients. No deaths 
occurred. Median fluoro time was 8.4 min (3.2 - 17.1). A procedure was classified as 
difficult when fluoro time was greater then 31.2 min (90th percentile). At a multivari-
ate analysis the predictors of a difficult procedure were the number of extracted 
leads (OR 1.71, 95%CI 1.06 – 2.8), the presence of screw leads (OR 5.68; 95%CI 1.9 
– 16.9), the presence of dual coil shock leads (OR 5.01, 95%CI 1.27 – 19.8), the years 
since the oldest lead was implanted (OR 1.23, 95%CI 1.15 – 1.31), the absence of leads 
with vegetation (OR 6.76, 95%CI 1.35 – 33.3). The female gender, the patient age at 
extraction, the presence of tachy leads, the presence of lead failure weren’t predic-
ObjectivOs: Identificar el impacto de la obligatoriedad de presentar una 
Evaluación Económica (EE) para la inclusión de medicamentos en el Cuadro Básico 
Nacional en las publicaciones de EE relacionada con el área de reumatología en 
México. MetOdOlOgíAs: Se realizó una búsqueda sistemática de las publi-
caciones de EE y reumatología publicados entre 1995 y 2011. Los estudios de EE 
fueron clasificados por tres expertos en economía de la salud con base a los criterios 
de Drummond, Sí los estudios contemplan comparación de dos o más alterna-
tivas y sí valoran los costos y consecuencias de las alternativas examinadas se 
dice que es un estudio de evaluación económica completa (EEC). Se valoró sí la 
modificación en el año 2003 tuvo impacto significativo en términos de número 
de publicaciones. ResultAdOs: Se identificaron un total de 263 artículos de EE 
entre 1995 y 2011, 93(35%) de fueron EEC. En el periodo 1995-2002 se identificaron 
56 estudios, 19(34%) EEC. En el periodo de 2003-2011 (después de la modificación 
del reglamento) se identificaron un total de 207 publicaciones de EE, 74(36%) EEC. El 
79% de las publicaciones se concentra en el periodo 2003-2011, con un total de 207 
publicaciones. Del total de publicaciones las relacionadas con reumatología fueron 
3% (n= 9) de las cuales 33% fueron completas, 67% fueron parciales. Se destaca que 
antes de la modificación del reglamento en 2003 se detectó un estudio de EE/reuma-
tología mientras que después del año 2003 el número de publicaciones ascendió a 8 
artículos. cOnclusiOnes: La EE en México a través del número de publicaciones se 
ha ido desarrollando notablemente, asimismo el hacer obligatorio el presentar un 
estudio de EE para la inclusión de un insumo al Cuadro Básico y Catálogo de Insumos 
del Sector Salud fue un punto de partida para el desarrollo de la EE en México.
ReseaRcH on MetHoDs – conceptual Papers
PRM16
a UnifieD MetHoDological fRaMewoRk foR tHe econoMic evalUation 
of tHeRaPeUtic MeDical Devices
Iglesias C.P.
University of York, York, UK
To inform policy decisions economic evaluation (EE) studies require the system-
atic identification and (quantitative) synthesis of the relevant evidence base on 
the clinical effectiveness, quality of life (QoL) and costs associated with the use of 
competing health technologies. Existing methods for EE are linked to principles of 
evidence-based medicine and, as such, are geared primarily towards the evaluation 
of pharmaceuticals. Some authors have claimed that medical devices (MDs) cannot 
be evaluated using the same principles. We take the opposite viewpoint and argue 
that used within the right evaluative framework existing EE methods are indeed 
appropriate to assess the cost effectiveness of therapeutic MDs. What makes the 
(economic) evaluation of MDs challenging is the fact that the quantity, quality, and 
characteristics of the evidence base around them, is often fragmented, heteroge-
neous and associated with high levels of uncertainty. In these circumstances it is 
important to acknowledge the value of eliciting and quantitatively summarising 
physicians and other experts’ beliefs regarding the effectiveness and resource use 
demands associated with MDs already in use. Using real life examples this paper 
shows how a Bayesian stepwise iterative approach has helped address some of the 
challenges associated with the EE of MDs, while guiding policy decisions regard-
ing technology adoption, research funding and design. Relevant steps include: a) 
identification of existing evidence base and elicitation of experts’ beliefs on clinical 
effectiveness , QoL and costs - i.e. “a priori evidence base”; b) quantitative synthesis 
of this a priori evidence base to inform the parameters of an EE model; (c) initial 
estimation of the model; d) assessment of the economic value of conducting fur-
ther research (VoI); e) collection of new patient level data (PLD) in a pilot study; 
(f) new evaluation of the EE model updating the prior estimates using primary PLD; 
g) further VoI analysis.
Disease-sPecific stUDies
caRDiovascUlaR DisoRDeRs – clinical outcomes studies
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Objectives: To determine the clinical consequences and it’s associated costs of the 
usage of oral anticoagulation therapy for the treatment of atrial fibrillation (AF) in 
Colombia by establishing the cost per disease related event. MethOds: We used a 
6-week cycle length, 17 functional state Markov model of the main clinical outcomes 
in the lifetime of a hypothetical cohort of 1,000 patient with AF per treatment arm. 
The pivotal clinical studies for apixaban, dabigatran, rivaroxaban compared to war-
farin were the source of safety and efficacy data. Data for the analysis was extracted 
from this literature using indirect comparison methods. Costs in Colombian pesos 
2012 are expressed in American dollars (1 US$ = COP$ 1785). To estimate costs, we 
analyzed resource use of a sample of 53 stroke, 148 myocardial infarction, 6 systemic 
embolism patients in San Ignacio University Hospital. Results were validated by an 
expert panel. Results: The number of events associated with each anticoagulant 
therapy (apixaban, dabigatran 110mg, dabigatran 150mg, rivaroxaban and warfarin, 
respectively) were: stroke and systemic embolism 349, 363, 351, 360, 369. ISTH major 
bleedings 235, 212, 233, 280, 277; clinically relevant non major bleedings 342, 337, 357, 
395, 383; myocardial infarctions 102, 114, 116, 101, 104; and event related deaths 459, 
485, 475, 469, 481. Apixaban could be associated with savings in non pharmacological 
cost of $ 360, $170, $145 and $311 per treated patient compared to dabigatran 110mg, 
dabigatran 150mg , rivaroxaban and warfarin, respectively. cOnclusiOns: In this 
